# US 2026/0083830 A1 · Biodegradable polymeric particles for delivery of positively charged therapeutic agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083830 A1
- Document ID: US20260083830A1
- Status: Published application
- Kind: A1
- Application number: 19/109,261
- Filed: 2023-09-06
- Published: 2026-03-26
- Earliest claimed: 2022-09-06
- Assignees: The Regents of the University of Michigan
- Applicants: Regents of the University of Michigan
- Inventors: Steven Paul Schwendeman; James Moon; Corrine Din
- Web page: https://patentgrep.com/patent/US20260083830A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/1694: {resulting in granules or microspheres of the matrix type containing more than 5% of excipient}
- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/5192: {Processes}
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/6093: {Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine}
- A61K 2039/627: {characterised by the linker}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure relates to microparticles and nanoparticles comprising a polymer matrix comprising an uncapped polymer and a net positively charged therapeutic agent at neutral pH. More particularly the disclosure relates to PLGA and/or PLA particles comprising an uncapped polymer for extended, controlled release of positively charged proteins or peptides at neutral pH. Methods of making the particles and administering the particles are also provided.

## Claims

### Claim 1

A particle for extended, controlled release of a therapeutic agent, comprising:
a polymer matrix, wherein the polymer matrix comprises a polymer chosen from poly(lactic-co-glycolic acid) (PLGA), poly(lactic acid) (PLA), or a combination thereof;
a therapeutic agent associated with and distributed in and encapsulated by the polymer matrix, wherein the therapeutic agent is net positively charged at neutral pH;
wherein at least some of the polymer is uncapped;
wherein the uncapped polymer comprises free carboxyl groups at the end of the polymer;
wherein the particle has an average particle diameter in the range of about 10 nm to about 10 μm;
wherein the particle has a therapeutic agent content in the range of about 2% weight percent (wt. %) to about 20% wt. %, based on the entire weight of the particle; and
wherein the particle has an initial burst release of the therapeutic agent of about 10% or less after 24 hours in a phosphate-buffered saline buffer.

### Claim 2 (depends on 1)

The particle of claim 1, wherein the uncapped polymer comprises PLGA.

### Claim 3 (depends on 1)

The particle of claim 1, wherein the uncapped polymer has a lactic acid content in the range of 25% to 100% and a molecular weight in the range of about 2 kDa to about 50 kDa.

### Claim 4 (depends on 1)

The particle of claim 1, wherein the uncapped polymer is PLGA and has a lactic acid content of about 75% and a molecular weight in the range of about 10 kDa to about 45 kDa.

### Claim 5 (depends on 1)

The particle of claim 1, wherein the therapeutic agent is a protein, peptide, or small molecule drug.

### Claim 6 (depends on 1)

The particle of claim 1, wherein the therapeutic agent has a molecular weight in the range of about 500 Da to about 5 kDa.

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9 (depends on 7)

The particle of claim 7, further comprising a counter ion, wherein a conjugate acid of the counter ion having a pKa in the range of about 0.1 to about 4.5.

### Claim 10

(canceled)

### Claim 11 (depends on 8)

The particle of claim 8, wherein the counter ion comprises HCOO−, or C1-5alkyl-COO−, the C1-5alkyl-COO− optionally substituted with a substituent chosen from one or more in the group of methyl, fluoro, chloro, or bromo.

### Claim 12 (depends on 1)

The particle of claim 1, wherein the counter ion is formate or trifluoroacetate.

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The particle of claim 1, wherein:
the uncapped polymer is PLGA;
the therapeutic agent has a net charge greater than or equal to about +1 at neutral pH, wherein the therapeutic agent comprises at least one positively charged amino acid residue coupled with a negatively charged counter ion, wherein a conjugate acid of the counter ion has a pKa in the range of about 0.1 to about 4.5, about 0.2 to about 4.0, or about 0.3 to about 3.5;
the particle has an average particle diameter in the range of about 500 nm to about 900 nm; and,
the particle has a therapeutic agent content greater than about 8 wt % based on the entire weight of the particle.

### Claim 16 (depends on 1)

The particle of claim 1, wherein:
the uncapped polymer is PLGA;
the therapeutic agent has a net charge greater than or equal to about +1 at neutral pH, wherein the therapeutic agent comprises at least one positively charged amino acid residue coupled with formate or trifluoroacetate as a counter ion;
the particle has an average particle diameter in the range of about 500 nm to about 900 nm; and,
the particle has a therapeutic agent content greater than about 8 wt % based on the entire weight of the particle.

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27 (depends on 1)

The particle of claim 1, having a substantially zero-order release profile.

### Claim 28 (depends on 1)

The particle of claim 1, wherein the particle has a substantially neutral zeta potential.

### Claim 29 (depends on 1)

The particle of claim 1, wherein therapeutic agent has moderate to low solubility in water.

### Claim 30

(canceled)

### Claim 31 (depends on 1)

The particle of claim 1, wherein the therapeutic agent has a net charge greater than or equal to about +1.5 at neutral pH.

### Claim 32 (depends on 1)

A formulation comprising a plurality of the particles of of claim 1 and a pharmaceutically acceptable excipient.

### Claim 33 (depends on 1)

A method of treating an autoimmune condition or disease, comprising administering to a subject in need thereof, the particle or formulation of claim 1.

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37

A method of making a particle for controlled release of a therapeutic agent, comprising:
providing a particle comprising a polymer matrix, the polymer matrix comprising a polymer chosen from one or more in the group of PLGA and PLA; and,
incubating the particles with a therapeutic agent in a liquid, thereby encapsulating the therapeutic agent in the polymer matrix;
wherein the particle has an average particle diameter in the range of about 10 nm to about 10 μm;
wherein at least some of the polymer is uncapped;
wherein the uncapped polymer comprises free carboxyl groups such that the particle includes free carboxyl groups;
wherein the therapeutic agent has a net positive charge at a neutral pH;
wherein the particle has a therapeutic agent content in the range of about 2% weight percent (wt. %) to about 20% wt. %, about 6 wt. % to based on the entire weight of the particle; and,
wherein the encapsulation efficiency of the therapeutic agent is in the range of about 40% to about 100%; and
wherein the particle has an initial burst release of therapeutic agent of about 10% or less, after 24 hours in a phosphate-buffered saline buffer.

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40

(canceled)

### Claim 41

(canceled)

### Claim 42

A method of making a particle for controlled release of a therapeutic agent, comprising:
providing a plurality of particles comprising a polymer matrix, the polymer matrix comprising an uncapped polymer chosen from one or more in the group of PLGA and PLA;
incubating the plurality of the particles with a therapeutic agent in an aqueous solvent, thereby encapsulating the therapeutic agent in the polymer matrix and forming a plurality of loaded particles; and
removing the solvent and drying the plurality of loaded particles;
wherein:
the uncapped polymer comprises free carboxyl groups such that the particle includes free carboxyl groups;
wherein the therapeutic agent comprises one or more positively charged amino acid residues at neutral pH;
wherein the positively charged amino acid residues of the therapeutic agent provide a net positive charge at neutral pH such that the net charge of the therapeutic agent is greater than or equal to about +1;
the concentration of the plurality of particles during incubation is in the range of about 100 mg/mL to about 300 mg/mL;
the concentration of the therapeutic agent during incubation is in the range of about 10 mg/mL to about 20 mg/mL; and
the plurality of particles are incubated at a temperature in the range of about 35° C. to about 45° C.

### Claim 43

(canceled)

### Claim 44

(canceled)

### Claim 45

(canceled)

### Claim 46

(canceled)

### Claim 47

(canceled)

### Claim 48

(canceled)

### Claim 49

(canceled)

### Claim 50

(canceled)

### Claim 51

(canceled)

### Claim 52

(canceled)

### Claim 53

(canceled)
